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Duchenne muscular dystrophy (DMD) is a progressive and fatal
genetic disorder of muscle degeneration. Patients with DMD lack
expression of the protein dystrophin as a result of mutations in
the X-linked dystrophin gene. The loss of dystrophin leads to severe
skeletal muscle pathologies as well as cardiomyopathy, which
manifests as congestive heart failure and arrhythmias. Like humans,
dystrophin-deficient mice (mdx mice) show cardiac dysfunction as
evidenced by a decrease in diastolic function followed by systolic
dysfunction later in life. We have investigated whether sildenafil
citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used
toameliorate the age-related cardiac dysfunctionpresent in themdx
mice. By using echocardiography, we show that chronic sildenafil
treatment reduces functional deficits in the cardiac performance of
aged mdx mice, with no effect on normal cardiac function in WT
controls. More importantly, when sildenafil treatment was started
after cardiomyopathy had developed, the established symptoms
were rapidly reversed within a few days. It is recognized that PDE5
inhibitors can have cardioprotective effects in other models of car-
diacdamage, but thepresent studyreportsapreventionand reversal
of pathological cardiac dysfunction as measured by functional anal-
ysis in a mouse model of DMD. Overall, the data suggest that PDE5
inhibitors may be a useful treatment for the cardiomyopathy affect-
ing patients with DMD at early and late stages of the disease.
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Duchenne muscular dystrophy (DMD) is a degenerative,muscle-wasting disease caused by mutations in the dystrophin
gene. The total loss of dystrophin profoundly impacts skeletal
muscle and causes impaired respiratory function, primarily in
older boys (1, 2). With improved noninvasive respiratory support,
patients with DMD experience increased lifespan and quality of
life, but also a higher incidence of complications and eventual
mortality from cardiomyopathy (3). Cardiomyopathy is a delayed
symptom of the disease that usually develops by the second decade
of life, with more than 90% of patients presenting clinical symp-
toms by 18 y of age (1). Loss of cardiac dystrophin eventually leads
to dilated cardiomyopathy, which manifests as congestive heart
failure in at least 20% of patients (1). Similarly, approximately
90% of patients with Becker muscular dystrophy, a milder form of
the disease, die of cardiac failure (1). Currently, angiotensin con-
verting enzyme inhibitors and β-blockers are used to treat heart
failure associated with DMD. Although these medications show
some benefit for patients with systolic heart failure, they have been
unsuccessful in treating dystrophic patients with features of systolic
and diastolic dysfunction (4). These findings highlight the need
for treatments that slow the development of cardiomyopathy in
DMD and improve cardiac function in older patients with estab-
lished cardiomyopathy.
NO-cGMP signaling pathways may provide a new potential tar-
get for therapeutic intervention inDMD.TheNO-cGMPpathways
are critical regulators of cardiac, smooth, and skeletal muscle
contractile function. NO is generated by Ca2+-sensitive NOS and
increases the production of cGMP by stimulating soluble guanylyl
cyclase activity. Loss of dystrophin prevents normal nNOS expres-
sion and/or signaling in all (skeletal, smooth and cardiac) muscle
systems (2). In fact, aberrant neuronal NOS (nNOS) signaling is
a common characteristic of many neuromuscular diseases (5).
Previous studies have shown that stimulation of cGMP synthesis
by overexpression of cardiac-specific nNOS reduces impulse-
conduction defects in dystrophin-deficient (mdx) mice (6, 7).
Similarly, increased particulate guanylyl cyclase activity in young
mdxmice has also been shown to decrease susceptibility to cardiac
damage during sympathetic stress (8). These data suggest that re-
duced NO-cGMP signaling is a key contributor to DMD cardiac
pathogenesis. Therefore, it seemed possible that restoration of NO
signaling, or the downstream consequences of nNOS signaling—
particularly increased cGMP second messenger levels—may pro-
vide therapeutic benefit to dystrophic hearts. In this study, we tested
whether blockade of cGMP breakdown using a phosphodiesterase
5 (PDE5) inhibitor might produce similar cardioprotective effects.
Sildenafil citrate is a cGMP-specific PDE5 inhibitor widely used
to treat erectile dysfunction (as Viagra; Pfizer) and pulmonary
hypertension (as Revatio; Pfizer). It has been previously suggested
that PDE5 inhibitors may have cardioprotective effects in themdx
mouse (8). These investigators reported that acute injections of
sildenafil reduced Evans blue dye uptake during mechanical stress
(8).However, itwasnot clearhow this result in very youngmdxmice
related to oldermdxmice with established cardiac dysfunction.We
report here both long-term protection and a rapid reversal of
established pathological cardiac dysfunction in the mdx mouse
model of DMD following chronic sildenafil treatment, some of
which have been presented in abstract form (9). Chronic sildenafil
treatment prevents functional deficits in the left ventricular per-
formance of aged mdx mice. Furthermore, when sildenafil treat-
ment is initiated after the cardiomyopathy has developed, the
established symptoms are rapidly reversed. Overall, the data sug-
gest that PDE5 inhibitors may be an effective treatment for DMD-
associated cardiomyopathy at early and late stages of the disease.
Results
Protection of Global Cardiac Function by Long-Term Sildenafil Treat-
ment.We used conventional echocardiography and tissue Doppler
analysis tomonitor the development of left ventricular dysfunction
in agingmdxmice. Both the myocardial performance index (MPI)
and ratios of early diastolic velocity (Ea) to peak velocity with atrial
contraction (Aa) were calculated.MPI is a sensitivemeasure of left
ventricular systolic and diastolic performance, whereas the Ea/Aa
largely reflects diastolic function. The majority of patients with
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DMD exhibit diastolic dysfunction and impaired myocardial per-
formance, which can be identified by increased MPI (10). This
dysfunction usually precedes the onset of systolic heart failure and
dilated cardiomyopathy (11). Mdx mice show these same echo-
cardiographic abnormalities (12, 13).
As shown in Fig. 1, we used three different sildenafil treatment
regimens: (i) long-term chronic sildenafil treatment starting at 1 mo
of age (Fig. 1B), (ii) long-term treatment starting at 12 mo with
echocardiographicmeasurements taken3mo later to assesswhether
established dysfunction could be reversed (Fig. 1C), and (iii) a sim-
ilar treatment starting at 12 mo, but with multiple measurements to
determine the time course of the reversal (Fig. 1D). We observed
impaired left ventricular performance inmdxmice (increasedMPI)
by 11 to 13 mo of age compared with treated and untreated WT
controls (Fig. 2A). As mice approach 15 mo of age, mdx mice con-
tinued to demonstrate impaired left ventricular function whereas
WTcontrolmicebegin to showa slight age-relateddecline incardiac
performance (Fig. 2 A and B). Sildenafil does not have an effect on
cardiac performance in WTmice (Fig. 2 A and B).
However, mdx mice that received chronic sildenafil treatment
starting at 1 mo of age retained a relatively normal MPI with age,
indicating that sildenafil attenuated the cardiomyopathy in mdx
mice (Fig. 2A). Interestingly, if sildenafil treatment was initiated
after cardiomyopathy developed at 12mo of age, theMPI returned
to normal by age 15 mo (Fig. 2A). These data indicate that silde-
nafil cannot only reduce the progression of, but also reverse, left
ventricular dysfunction within 3 mo of starting treatment.
Rapid Reversal of Cardiac Dysfunction by Short-Term Sildenafil
Treatment. To determine the time required for sildenafil treat-
ment to reverse left ventricular dysfunction, we closely monitored
the MPI of a subset of 12-mo-old mdx mice with established car-
diac dysfunction. A baseline MPI measurement was collected
before a 2-wk sildenafil treatment regimen. Multiple MPI meas-
urements were taken during and after sildenafil administration
(Fig. 1D). Remarkably, the MPI was significantly improved within
3 d of initiation of sildenafil treatment (Fig. 2C), and this effect was
sustained throughout the course of 3mo (Fig. 2A).Moreover, after
removal of sildenafil, theMPI remained normal for approximately
10 d before it progressively deteriorated to the pretreatment levels
(Fig. 2C). As sildenafil is metabolized with a half-life of approxi-
mately 20min inmice, it is highly unlikely that residual drug will be
present 10 d after removal. This rapid and sustained improvement
suggests that the effect of acute sildenafil treatment is independent
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Fig. 1. Timelines of the different sildenafil treatment regimens. (A) Un-
treated control with echocardiographic measurements at approximately 4,
8, 12, and 15 mo of age; (B) chronic sildenafil treatment beginning at 1 mo
of age for prevention analysis; (C) acute sildenafil treatment beginning at
12 mo of age for reversal analysis; and (D) 2-wk sildenafil treatment starting
at 12 mo of age with successive echocardiographic measurements before,
during, and after treatment (Inset, close-up of timeline with black lines
representing echocardiographic time points). Sildenafil treatment started on
day 0, with echocardiographic measurements on days 3, 7, and 14. Sildenafil
was removed and echocardiograms acquired on days 18, 24, 31, and 40.
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Fig. 2. Left ventricular dysfunction is reduced and reversed in mdx mice. (A)
Pulse-wave Doppler MPI timeline of mdx and WT mice. Sildenafil treatment
prevents an increase in MPI to 15 mo and reverses the abnormal MPI when
administration begins at 12 mo. (B) Tissue Doppler Ea/Aa ratio timeline. Val-
ues are means ± SE; *P < 0.05,mdx vehicle vs. WT vehicle; #P < 0.05,mdx after
3 mo of sildenafil treatment (15 mo old) vs. baseline at 12 mo; n = 4–12 mice/
group; two-way ANOVA. (C) MPI of 12 mo-old mdx mice before, during, and
after a 2-wk sildenafil treatment regimen. MPI is expressed as a percentage
change from baseline before sildenafil administration. Sildenafil treatment
started on day 0, with MPI acquisition on days 3, 7, and 14. Sildenafil was
removed and MPI acquired on days 18, 24, 31, and 40. Values are means ± SE;
*P < 0.05 for time points compared with baseline; n = 6 mice; one-way
ANOVA. (D) MPI was obtained by pulse-wave Doppler imaging of mitral valve
inflow (Right) from the apical four-chamber view (Left). RV, right ventricle;
LV, left ventricle; RA, right atrium; LA, left atrium; IVCT, isovolumic contrac-
tion time; IVRT, isovolumic relaxation time; EV, left ventricular ejection time.
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of long-term cardiac remodeling. Instead, the mechanism un-
derlying improved cardiac performance occurs relatively rapidly in
just a matter of days. This is not consistent with the beneficial
effects of sildenafil being directly caused by long-term changes in
fibrosis or rapid acute changes in cardiovascular tone.
Diastolic Dysfunction Is Improved After Sildenafil Treatment in mdx
Mice. As the improvement by sildenafil in the MPI could be a re-
sult of effects on systolic or diastolic function, we measured the
Ea/Aa using tissue Doppler imaging to more directly evaluate
diastolic function inmdxmice. This parameter largely reflects the
diastolic (chamber relaxation and filling) capacity of the left
ventricle. As shown in Fig. 2, diastolic dysfunction (indicated by
Ea/Aa <1) was observed inmdxmice as early as 8 mo of age (Fig.
2B). Moreover, chronic sildenafil treatment reduced the pro-
gression of diastolic dysfunction in mdx mice through 15 mo of
age. Similarly, sildenafil initiated at 12 mo of age, after the dys-
function had developed, also largely reversed the diastolic dys-
function by 15 mo (Fig. 2B). This result is consistent with the
effect of sildenafil on improvement seen in theMPI and therefore
suggests that diastolic dysfunction is a major component of the
impaired MPI observed in 11- to 13-mo-old mdx mice.
Sildenafil Alters Cardiac Dimensions. Cardiac remodeling after in-
jury can result in hypertrophy, increased fibrosis and systolic
dysfunction of the heart. Cardiomyopathy in mdx mice is char-
acterized by slow, progressive cell death, followed by compensa-
tory hypertrophy of remaining cardiomyocytes and eventual
replacement fibrosis. We used M-mode echocardiography to de-
termine left ventricular dimensions in conscious mdx mice. Al-
though the mdxScSn strain develops overt cardiac hypertrophy
(12), this is much less apparent in the mdx4cv strain used in all
these studies (Table 1). Nevertheless, by 12 mo of age, the left
ventricular walls of mdx4cv mice were thicker and the left ven-
tricular mass index (LVMI) larger compared with sildenafil-
treated mdx4cv mice (Table 1). This effect of sildenafil on wall
thickness, in addition to the acute effects on diastolic function,
suggests that sildenafil may also have protective effects on some
aspects of cardiac remodeling. However, we found no differences
in the percent of fractional shortening (FS) percentage of 12-mo-
old, consciousmdxmice compared withWT controls or sildenafil-
treatedmdxmice. There was also no effect on heart rate (Table 1).
This indicates a lack of major systolic dysfunction in these animals
up to 12 mo of age. Although systolic dysfunction may develop
later in life, it appears that diastolic dysfunction plays a more
prominent role in the cardiomyopathy seen in mdx4cv mice.
GSK-3β Phosphorylation Is Up-Regulated After Long-Term Sildenafil
Treatment. Theunexpected rapid reversal of the cardiac dysfunction
caused by sildenafil greatly constrained our ideas about the molec-
ularmechanism(s) by which the drugmight be acting. It is likely that
several molecular mechanism(s) could be altered by sildenafil that
may lead to improved cardiac function. In studies of the protective
effects of this drug on cardiac ischemia/reperfusion injury, sildenafil
has been reported to up-regulate cGMP-dependent protein kinase
G (PKG) and PKG-dependent phosphorylation of glycogen syn-
thase kinase 3β (GSK-3β) (14). As this effect of sildenafil was po-
tentially relevant to the timecourseobserved for thereversal studies,
wemeasuredPKGprotein expression andGSK-3β phosphorylation
in the ventricular tissue from 16-mo-old mdx mice after long-term
sildenafil treatment. As shown in Fig. 3, both increased PKG ex-
pression and GSK-3β phosphorylation were seen (Fig. 3 A–C).
Thus, long-termsildenafil treatmentof dystrophin-deficient animals
may initiate protective mechanisms similar to those responsible for
protection from ischemia-reperfusion injury. However, additional
studies will be needed to prove this hypothesis.
Discussion
We have investigated the impact of long-term oral administration
of sildenafil on prevention of cardiac dysfunction and restoration
of MPI in mdx mice. This study identifies an apparent strong
therapeutic effect of sildenafil on the abnormal MPI and Ea/Aa
ratios in mdx mice. To our knowledge, this is the first report of
rapid reversal by a drug treatment of the functional symptoms
seen in the established cardiac dysfunction that occurs in mdx
mice. Although several studies have described protective effects
of sildenafil against other forms of cardiac myopathy and hyper-
trophy (2), to our knowledge, the only study to date on the effects
of sildenafil on dystrophic cardiac dysfunction has reported that
repeated injections of sildenafil in very young mdx mice can re-
duce cardiomyocyte susceptibility to mechanical injury (8). The
same study also reported a reduction in several possible early
markers of cardiomyopathy seen before the onset of cardiac
dysfunction (8). It is well established that oldermdxmice show an
increase in cardiac mass and diastolic dysfunction (12, 15–17),
providing us an excellent model to examine the effects of sildenafil
on established cardiomyopathy. In fact, one study has reported the
development of cardiac hypertrophy inmdxmice as early as 16 to
21 wks (12), suggesting that the reduced wall thickness we see in
the chronically sildenafil-treated 12-mo-old mdx mice may be in-
dicative of a long-term, sustained improvement.
Interpretation of the possible mechanism(s) by which sildenafil
might be improving the MPI and Ea/Aa ratio are made difficult by
the fact that little is known about why these echocardiographic
parameters are altered in the mdx mouse heart. In principle, the
cardioprotective effects of sildenafil could be caused by enhanced
systolic or diastolic function.Weobserved no systolic dysfunction in
12-mo-old mdx mice, which is consistent with findings from Jear-
awiriyapaisarn et al. (12). Previous reports suggest that systolic
dysfunction may develop with age (15–18). The reasons for these
discrepancies arenot known,butmaybe related todifferences in the
mdx strains used or perhaps other differences in genetic back-
grounds.Becausewedonot see systolicdysfunction inmdxmice, the
poor cardiac performancemeasuredbyMPI seemsmost likely to be
a result of diastolic dysfunction. This interpretation is supported by
tissue Doppler imaging measurements of diastolic function. A di-
astolic Ea/Aa ratio is typically at least 1, with values less than 1
reflecting abnormal wall relaxation/filling. The changes we see in
Ea/Aa ratio upon sildenafil treatment reinforce the idea that the
major cardiac dysfunction in 12- to 15-mo-oldmdxmice is diastolic
in nature. As wt controls do not display cardiac dysfunction, we do
not see an effect with sildenafil treatment. Currently, there are no
validated therapeutic approaches that effectively target diastolic
dysfunction (19). Thus, cGMPenhancement by sildenafil may be an
effective treatment of other forms of diastolic dysfunction.
Neither the target cells nor molecular mechanism(s) for silde-
nafil’s cardioprotective effects are clear. Previous reports suggest
that cGMP-mediated activation of PKG signaling can occur in
cardiomyocytes (20). Increased PDE5 expression also has been
Table 1. Cardiac dimensions and systolic function of treated
12-mo-old mdx mice
Parameter WT mdx mdx (sildenafil)
No. of mice 7 18 12
BW, g 35.59 ± 0.6 34.12 ± 0.2 34.47 ± 0.2
IVSd, mm 1.05 ± 0.01 1.06 ± 0.01 0.92 ± 0.01*
LVIDd, mm 3.22 ± 0.04 3.16 ± 0.02 3.32 ± 0.02
PWd, mm 0.95 ± 0.02 1.03 ± 0.01 0.89 ± 0.01*
FS, % 52.74 ± 0.5 47.23 ± 0.3 51.78 ± 0.5
LVMI, mm/g 3.24 ± 0.1 3.48 ± 0.03 3.00 ± 0.03*
HR, beats/min 629 ± 7.0 616.28 ± 3.6 597.43 ± 8.9
BW, body weight; HR, heart rate. Values are means ± SE analyzed by two-
way ANOVA.
*P < 0.05 mdx compared with mdx (sildenafil).









reported in rat cardiomyocytes during cardiac hypertrophy and
remodeling, suggesting that sildenafil may act directly on car-
diomyocytes (21). However, others have not observed this effect
in cardiomyocytes isolated from mice (22). Even though it is un-
clear which cell type is targeted by sildenafil, total heart extracts
from patients with end-stage congestive heart failure have in-
creased PDE5 expression via a mechanism involving oxidative
stress (23), and a recent study has shown an increase in oxidative
stress in the hearts of youngmdxmice (24). Whether this increase
in PDE5 expression takes place in cardiomyocytes, myofibro-
blasts, or vascular smooth muscle cells is still to be determined.
In addition, one cannot rule out other PDEs as a potential
target for sildenafil. We detected a mean free plasma concen-
tration of sildenafil to be approximately 70 nM, sufficient to
greatly inhibit PDE5 (Fig. S1), but given the high rate of metab-
olism of sildenafil in mice, peak levels of the drug may be high
enough to inhibit other PDEs such as PDE1C. With an IC50 of
280 nM, partial inhibition of PDE1C could explain some of the
cardioprotective effects seen in this study, especially as PDE1C is
highly expressed in cardiomyocytes and vascular smooth muscle.
Future experiments using other PDE5 inhibitors, such as tadalafil
(Cialis; Eli Lilly) which does not inhibit PDE1C, could provide
insight on the molecular mechanism(s) by which sildenafil has
a cardioprotective effect in mdx mice.
Finally, at least some of the beneficial effects of long-term
treatment by sildenafil observed in this study could be explained by
PKG-dependent phosphorylation of GSK-3β (Fig. 3) (14, 25, 26).
Phosphorylation of GSK-3β (Ser9) has been associated with car-
dioprotection in ischemia/reperfusion models of cardiac damage,
inwhich treatment with sildenafil decreased infarct size in anAKT-
independent manner (14). Other studies have shown that GSK-3β
kinase activity is inhibited by PKG-dependent phosphorylation,
resulting in decreased apoptosis and fibrosis and ultimately in-
creased contractility (27). The improvements in cardiac function
seenwith sildenafil in the present studiesmay result, at least in part,
from similar mechanisms. However, given the short time scale of
the reversal, additionalmechanisms are also likely to be important,
such as effects on mitochondrial biogenesis and function (28).
All the possible mechanisms discussed here assume that the
cardioprotective effects result from actions on the cardiomyocytes.
However, cardiomyocyte-independent mechanisms also could be
responsible for part or all the improved cardiac performance. As
PDE5 is highly expressed in vascular smooth muscle, sildenafil-
mediated vasodilation may reduce cardiac afterload and improve
cardiac performance. Mice lacking nNOS or dystrophin cannot
properly regulate blood flow during exercise and have impaired
vascular perfusion as well as functional ischemia (6). Thus, silde-
nafil-mediated enhancement of blood flow in exercised dystrophic
muscle (5) may also contribute to the therapeutic effect of the drug
on cardiac function. This idea is consistent with the hypothesis that
contracting muscles, such as the heart, require enhanced NO-
cGMP signaling, such as might be provided by PDE5 inhibition.
Regardless of its molecular mechanisms of action, sildenafil
citrate is currently approved for short-term human use in treat-
ment of erectile dysfunction (Viagra) and long-term use in treat-
ment of pulmonary hypertension (Revatio). Our study used
a comparable dose of sildenafil as those used for chronic treatment
of pulmonary hypertension (Fig. S1). To our knowledge, this study
is the first to report a treatment using an Food and Drug Ad-
ministration-approved drug that can reverse established left ven-
tricular dysfunction within 3 d of drug administration andmaintain
normal function (based on pulse-wave Doppler analysis of MPI)
for a minimum of 3 mo. Although PDE5 inhibitors will certainly
not cure DMD, the current studies suggest that they could be used
in combination with current or future therapies. In fact, targeting
skeletal muscle repair without cardiac treatment exacerbates
damage to the heart, emphasizing the importance for a cardiac-
specific treatment (29). Other developing therapies for DMD in-
clude modulation of exon splicing (i.e., exon skipping) and gene
transfer (13). Although these technologies could be a potential
cure for DMD, their mainstream use is likely to be years away. In
summary, the cardioprotective effects we see suggest that sildenafil
can be useful as a preventive therapy for the cardiomyopathy that
develops in muscular dystrophy and may also effectively reverse
established diastolic dysfunction seen in patients with DMD.
Methods and Materials
Animal Models. All animals used in these studies were of the mdx4cv strain.
mdx4c breeding pairs were a gift from Jeff Chamberlain (University of
Washington, Seattle). The breeding pairs consisted of mdx mice (B6Ros.Cg-
Dmdmdx-4Cv/J) and WT mice (C57BL/6). All animals were housed in a specific
pathogen-free facility and the study was approved by the University of
Washington Institutional Animal Care and Use Committee. Male mice were
weaned at 4 wks of age, some of which were immediately started on chronic
sildenafil treatment.
Oral Administration of PDE5A Inhibitor. Sildenafil citrate (100-mg tablets;
Viagra; Pfizer) was dissolved in acidified water (pH 3.0) to a final concen-



















































Fig. 3. Sildenafil-mediated cardioprotection in 16-mo-old mdx hearts is
associated with inactivation of GSK-3β. (A) Representative Western blots
showing relative abundance of PKG, pGSK-3β, GSK-3β, and GAPDH. (B) PKG
protein expression normalized to GAPDH and (C) pGSK-3β protein expres-
sion normalized to total GSK-3β; n = 7 mice/group; *P < 0.05 analyzed by
unpaired t test.
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ingestion of approximately 80 mg/kg/d. The IC50 for sildenafil inhibition of
50% of PDE5A is 10 nM.
Echocardiography. Transthoracic, 2D-guided M-mode echocardiography was
obtainedat the levelof thepapillarymusclesonconsciousmiceat12moofage.
Every attempt was made to keep the operator blinded to mouse type and
treatment, but there were noticeable phenotypic differences. Thus, analysis
was performed blinded and on separate days from acquisition. For conscious
echocardiography (Vevo 770; VisualSonics), a 30-Mhz high-frequency trans-
ducer was used (RMV 707B). The mouse was held in the prone position by
restraining their limbs with elastic bands. Mice were trained 1 d before col-
lecting experimental images by applying gel and touching the chest with the
probe for at least 5min. Cardiac dimensions, heart rate, and the percentage of
fractional shortening (FS)were obtained. FSwas calculatedas (LVIDd− LVIDs) /
LVIDd × 100%, where LVIDd is the left ventricular internal dimension at end-
diastole and LVIDs is the left ventricular internal dimension at end-systole.
LVMI was calculated by as 1.04 * (IVSd + LVIDd + PWd)3 – (LVIDd3), where IVSd
is the interventricular septal thickness at end-diastole, PWd is the posterior
wall thickness at end-diastole, and LVIDs is the left ventricular internal di-
mension at end-systole.
Anesthetized Doppler analyses were performed by using an Acuson CV-70
unit (Siemens) equipped with a 13-MHz probe. Isoflurane 0.5% to 1% mixed
with O2 was administered to provide adequate sedation while minimizing
cardiac suppression during echocardiography. An increase in MPI is an in-
dication that a greater fraction of systole is spent to cope with the pressure
changes during isovolemic phases, which has been shown to be a sign of left
ventricular systolic and diastolic dysfunction (30). The MPI was obtained by
using pulse-wave Doppler imaging ofmitral valve inflow from the apical four-
chamber view as (IVCT + IVRT) / LVET, where IVCT is the isovolumic contraction
time, IVRT is the isovolumic relaxation time, and LVET is left ventricular
ejection time. For the 2-wk sildenafil treatment regimen (Fig. 2C), theMPI was
measured using the VisualSonics Vevo 770 unit with a 30-Mhz high-frequency
transducer (RMV 707B) to obtain higher resolution for analysis. For tissue
Doppler measurements, sample volume was placed within the left posterior
wall of the myocardium at the level of the papillary muscles to align the
sample volume parallel with the Doppler flow by angle correction to opti-
mally assess flow velocities. Doppler tissue peak Ea and peak Aa were used to
determine the Ea/Aa ratio.
Protein Extraction and Western Blot Analysis. Frozen ventricles were ground to
a powder using a mortar and pestle precooled with liquid nitrogen, and then
rotor-homogenized (Ultra Turrax) in extraction buffer [100 mM Tris-HCl, pH 8,
1% SDS, 1% deoxycholate-sodium, 20 mM EDTA, plus one Protease Inhibitor
Mixture Tablet (Roche) per 10 mL and one Phostop Tablet (Roche) per 10 mL
protein (20 μg)], separatedby SDS/PAGE, and transferred to a PVDFmembrane.
The membrane was incubated overnight with primary antibodies for pGSK-3β
(Ser9), GSK-3β, GAPDH (Cell Signaling Technology), or PKG (Calbiochem). The
membrane was washed in 0.5% Tween-20 in tris-buffered saline solution, in-
cubated with HRP-conjugated donkey anti-rabbit secondary antibody for 1 h
at room temperature, thenwashed again. The blots were developed using the
Supersignal West Femto chemiluminescence detection system (Pierce). Bands
were imaged using a CCD (Alpha Innotech) and band intensity was measured
using ImageJ software. GAPDH was used as sample loading control.
Statistical Analysis. Data are presented as mean ± SE unless otherwise speci-
fied. Two-way analysis of variance followed by a post-hoc test was used to
assess statistical significance.
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